Table 2b.

Unweighted means for baseline and time-varying confounders for each treatment group between 6- and 9-months relative to the population mean and standard deviation (SD).

	Treatment Group Between 6 and 9-Months
	Residential (N= 246)	Outpatient (N= 263)	BDS only (N= 753)	No Treatment (N=1608)	Population Mean (SD)
Female	0.22	0.25	0.22	0.24	0.24 (0.42)
Race/ethnicity
White	0.53	0.58	0.53	0.60	0.57 (0.50)
Black	0.22	0.13	0.17	0.18	0.17 (0.38)
Hispanic	0.11	0.14	0.16	0.11	0.13 (0.34)
Other	0.14	0.15	0.14	0.11	0.13 (0.33)
Age	15.91	16.08	15.93	15.99	15.97 (1.35)
Baseline SFS	0.24^*	0.19	0.18	0.16	0.18 (0.18)
Baseline SPSm	4.79^*	3.96	3.81	3.54	3.81 (4.23)
Baseline SPSy	9.64^*	8.20	8.73	7.45	8.17 (4.66)
Baseline EPS	0.29	0.28	0.27	0.24	0.26 (0.21)
Baseline days in controlled environment	17.81	19.65^*	15.23	10.53	13.95 (24.59)
SFS at 3-months	0.07	0.07	0.07	0.08	0.07 (0.11)
SPSm at 3-months	2.29	2.35	2.37	2.14	2.25 (3.36)
EPS at 3-months	0.27^*	0.24	0.22	0.20	0.22 (0.19)
Days ctrl. environ. at 3-months	44.12^*	23.95	18.06	13.05^*	19.37 (29.07)
SFS at 6-months	0.08	0.07	0.09	0.09	0.08 (0.13)
SPSm at 6-months	1.99	2.05	2.27	2.02	2.10 (3.35)
EPS at 6-months	0.27^*	0.22	0.19	0.18	0.20 (0.18)
Days ctrl. environ. at 3-months	49.97^*	16.31	11.12	8.50^*	14.81 (28.44)
Treatment group at 3-months
No treatment	0.03	0.06	0.04	0.07	0.05 (0.23)
BDS only	0.08	0.10	0.15	0.12	0.12 (0.33)
Outpatient	0.37^*	0.46	0.55	0.60	0.54 (0.50)
Residential	0.52^*	0.38^*	0.25	0.21	0.28 (0.45)
Treatment group at 6-months
No treatment	0.10^*	0.12^*	0.20^*	0.47^*	0.30 (0.46)
BDS only	0.15^*	0.20^*	0.47^*	0.29	0.32 (0.47)
Outpatient	0.14^*	0.50^*	0.26	0.20	0.25 (0.43)
Residential	0.60^*	0.18	0.08	0.05^*	0.13 (0.34)
Mean dosage^* of treatment (interquartile range)	51 (16, 90)	16 (4, 20)	6 (1, 7)	NA	NA

Denote if PSB comparing the group in question to the population was greater than 0.20.

Dosage of treatment is measured in days for residential treatment and number of times for outpatient and BDS.